Aptamers for Targeted Treatment
The July issue of European Bio-pharmaceutical Review is all about affinity ligands. The focus of this issue is not just on antibodies and as aptamer experts we were asked to write a review on Targeted Treatment using aptamers.
The use of antibody-drug conjugates has become particularly prevalent in cancer therapy, although their development can be problematic in their execution. However, aptamers can be used as alternative affinity ligands to overcome these drawbacks. Additional insight from the technical team at Aptamer Group can be found below:
Alternatively you can read the article on the Samedan website.
If you want to find out more about aptamers and Aptamer Group, please contact us using the form below.
This article is taken from European Biopharmaceutical Review July 2018, pages 38-44. © Samedan Ltd.